Ocrelizumab shows the highest association with urinary tract infections in patients with MS according to an FDA Adverse Event ...
Satralizumab significantly reduces relapse risk in patients with relapsing MOGAD, according to phase 3 METEOROID trial results presented at AAN 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results